CP
ARKG icon

Camelot Portfolios’s ARK Genomic Revolution ETF ARKG Stock Holding History

Camelot Portfolios’s Portfolio ARKG Stock Details ARKG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-11
Closed -$319 – 211
2025
Q4 		$319 Buy
+11
New +$330 ﹤0.01% 574
2024
Q3 		– Sell
-22
Closed -$517 – 158
2024
Q2 		$517 Buy
+22
New +$555 ﹤0.01% 572

Other funds holding ARKG

JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $49.6B AUM 39.59% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Camelot Portfolios's ARKG Position: Q1 2026 in Review

Camelot Portfolios sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 11 shares — an estimated $319 sold.

Camelot Portfolios first reported a position in ARKG in Q2 2024 and held it in 2 quarters. The position peaked at $517 in Q2 2024. 219 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Camelot Portfolios reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
  • Camelot Portfolios sold 11 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $319.
  • Camelot Portfolios first reported a position in ARK Genomic Revolution ETF in Q2 2024 and held it in 2 quarters.
  • Camelot Portfolios's ARK Genomic Revolution ETF position peaked at $517 in Q2 2024.
  • 219 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Camelot Portfolios's 13F filing for Q1 2026, filed 8 May 2026.